Executive Summary
NASA's $109.2M delivery order to Caltech (JPL FFRDC) for EMIT Earth mineral dust investigation and operations through 2028 underscores stable long-term federal space R&D funding, with $90.3M outlayed to date. Neutral direct equity implications due to nonprofit recipient, but $16.2M unexercised options signal potential modest upside.
Single-record concentration highlights execution risks tied to future task orders amid no commercial equity exposure.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior Contract Option Exercises digest from March 15, 2026.
Investment Signals (1)
- JPL FFRDC Program Continuity (HIGH)▲
$109.2M obligation (ceiling $125.4M) affirms NASA's non-competed commitment to space science R&D over 10-year span.
Risk Flags (1)
- Execution [MEDIUM RISK]▼
Realization of full $109.2M obligation and $125.4M ceiling depends on future NASA task orders over extended period to 2028-09-30.
Opportunities (1)
- ◆
$16.2M unexercised options and ongoing FFRDC sponsorship enable additional NASA task orders through 2028.
Sector Themes (1)
- ◆
Non-competed cost-plus-fixed-fee delivery order to Caltech/JPL concentrates on space science R&D (NAICS 541715, PSC AR22).
Watch List (1)
- 👁
{"entity"=>"Caltech/JPL NASA Contracts", "reason"=>"10-year term with $16.2M unexercised options and task order reliance amid $90.3M outlays.", "trigger"=>"Option exercises reaching $125.4M ceiling or new awards"}
Get daily alerts with 1 investment signals, 1 risk alerts, 1 opportunities and full AI analysis of all 1 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: Contract Option Exercises
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
S&P 500 Technology Sector SEC Filings — May 27, 2026
S&P 500 Technology Sector SEC Filings
May 27, 2026
Orphan Drug Approvals — May 27, 2026
Orphan Drug Approvals
May 27, 2026
Big Pharma Approvals — May 27, 2026
Big Pharma Approvals